β-上腺和Hippo通路信号的合:对心力衰竭病理生理学和代谢疗法的影响
Xiao-Jun Du1, Gang She2, Wei Wu3
1Department of Physiology and Pathophysiology, School of Basic Medical Sciences, and Key Laboratory of Environment and Genes Related to Diseases, Ministry of Education, Xi'an Jiaotong University Health Science Center, 76 West Yanta Road, Xi'an, Shaanxi 710061, China; Baker Heart and Diabetes Institute, 75 Commercial Road, Melbourne, Victoria 3004, Australia,.
Mitochondrion
|August 9, 2024
概括
交感β-上腺素受体 (βAR) 系统和Hippo通路激活有助于心力衰竭 (HF). 阻断βAR信号可能通过减轻不良心脏影响来提供治疗效益.
科学领域:
- 心血管生物学 心血管生物学
- 分子心脏病学分子心脏病学
- 细胞信号传递 细胞信号传递
背景情况:
- 交感β-上腺素受体 (βAR) 系统激活是心脏病和心力衰竭 (HF) 进展的核心.
- 河马通路在心肌病症中发挥着关键作用,在人类心脏病中观察到它的激活和YAP-TEAD1无活化.
- β-上腺素受体刺激激活心脏Hippo通路,导致YAP/TAZ无活化.
研究的目的:
- 审查目前对βAR信号与心力衰竭中的Hippo通路之间的相互作用的理解.
- 突出这一信号轴在线粒体功能障碍,代谢重编程和不良心脏重塑中的作用.
- 讨论针对HF中βAR-Hippo通路的治疗含义.
主要方法:
- 对βAR信号传递,Hippo通路和心力衰竭现有临床和实验研究的综述.
- 对将βAR激活与Hippo通路调节联系起来的分子机制的分析.
- 检查对心肌细胞功能,纤维化和新陈代谢的影响.
主要成果:
- βAR-Hippo通路的激活促进心肌细胞死亡,纤维化,线粒体功能障碍和心脏中的代谢重编程.
- 这种信号级联降低了线粒体和代谢基因的调节,同时上调了促炎和促纤维的因素.
- β-上腺抗剂可以阻止βAR和Hippo通路信号的合.
结论:
- βAR信号和Hippo通路的融合为HF的病变发生提供了至关重要的见解.
- 了解这种相互作用对于评估β-对抗剂的疗效和开发新型代谢疗法对HF至关重要.
- 对这一途径的进一步研究有望改善高频管理.
相关概念视频
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
406
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
406
01:22Heart Failure Drugs: β-Blockers
326
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
326
01:22Heart Failure Drugs: Diuretics
353
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
353
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K
01:26Heart Failure Drugs: Inotropic Agents
548
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
548